| Budget Amount *help |
¥14,650,000 (Direct Cost: ¥12,100,000、Indirect Cost: ¥2,550,000)
Fiscal Year 2009: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2008: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2007: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2006: ¥3,600,000 (Direct Cost: ¥3,600,000)
|
|---|
| Research Abstract |
We observed an abrupt increase of G2P[4] strains in Brazil after the introduction of the monovalent G1P[8] rotavirus vaccine. In clinical trials, the effectiveness of the monovalent vaccine against fully-heterotypic G2P[4] strains was not well established because the circulating strains at the time of clinical trials were mainly G1P[8] strains. Thus, this study was undertaken to assess the vaccine effectiveness against G2P[4] strains using the case-control design. Among children aged 6-11 months, the effectiveness of the monovalent vaccine was 77% against severe G2P[4] diarrhoea, and 83-85% against hospitalization. The G1P[8] monovalent vaccine was shown to be effective against severe diarrhoea due to G2P[4] rotavirus strains in an impoverished setting in Latin America.
|
